Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

INTRAMYOCARDIAL BONE MARROW STEM CELLS IN PATIENTS UNDERGOING CARDIAC SURGICAL REVASCULARIZATION.

Chan JL, Miller JG, Zhou Y, Robey PG, Stroncek DF, Arai AE, Sachdev V, Horvath KA.

Ann Thorac Surg. 2019 Sep 14. pii: S0003-4975(19)31394-3. doi: 10.1016/j.athoracsur.2019.07.093. [Epub ahead of print]

PMID:
31526779
2.

Advances in T-cell Immunotherapies.

Stroncek DF, Reddy O, Highfill S, Panch SR.

Hematol Oncol Clin North Am. 2019 Oct;33(5):825-837. doi: 10.1016/j.hoc.2019.05.006. Epub 2019 Jul 4. Review.

PMID:
31466607
3.

Humanized mouse models reveal an immunologic classification of idiopathic CD4 lymphocytopenia subtypes.

Perez-Diez A, Liu X, Sheikh V, Roby G, Stroncek DF, Sereti I.

JCI Insight. 2019 Jul 25;4(14). pii: 127802. doi: 10.1172/jci.insight.127802. eCollection 2019 Jul 25.

4.

Overcoming Challenges in Process Development of Cellular Therapies.

Highfill SL, Stroncek DF.

Curr Hematol Malig Rep. 2019 Aug;14(4):269-277. doi: 10.1007/s11899-019-00529-5. Review.

PMID:
31278568
5.

Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.

Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, Highfill SL, Li X, Dagur P, Kochenderfer JN, Fry TJ, Mackall CL, Lee D, Shah NN, Stroncek DF.

Mol Ther. 2019 Jul 3;27(7):1275-1285. doi: 10.1016/j.ymthe.2019.05.015. Epub 2019 May 30.

PMID:
31178392
6.

How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?

Chen LN, Collins-Johnson N, Sapp N, Pickett A, West K, Stroncek DF, Panch SR.

Transfusion. 2019 Aug;59(8):2506-2518. doi: 10.1111/trf.15349. Epub 2019 May 28.

PMID:
31135995
7.

Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics.

Elavia N, Panch SR, McManus A, Bikkani T, Szymanski J, Highfill SL, Jin P, Brudno J, Kochenderfer J, Stroncek DF.

Transfusion. 2019 May;59(5):1755-1764. doi: 10.1111/trf.15287. Epub 2019 Apr 11.

PMID:
30973976
8.

Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use.

Green DS, Nunes AT, Tosh KW, David-Ocampo V, Fellowes VS, Ren J, Jin J, Frodigh SE, Pham C, Procter J, Tran C, Ekwede I, Khuu H, Stroncek DF, Highfill SL, Zoon KC, Annunziata CM.

J Transl Med. 2019 Mar 14;17(1):82. doi: 10.1186/s12967-019-1822-6.

9.

Cell therapies for trauma and critical care medicine: critical issues in translation for cellular and novel therapies in trauma and critical care.

Stroncek DF, Mathew AJ, McKenna DH.

Transfusion. 2019 Feb;59(S1):854-857. doi: 10.1111/trf.14832. No abstract available.

PMID:
30737821
10.

Single cell sequencing reveals gene expression signatures associated with bone marrow stromal cell subpopulations and time in culture.

Liu S, Stroncek DF, Zhao Y, Chen V, Shi R, Chen J, Ren J, Liu H, Bae HJ, Highfill SL, Jin P.

J Transl Med. 2019 Jan 11;17(1):23. doi: 10.1186/s12967-018-1766-2.

11.

Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993-2010): factors that predict intensity and time to transfusion independence.

Griffith LM, VanRaden M, Barrett AJ, Childs RW, Fowler DH, Kang EM, Tisdale JF, Klein HG, Stroncek DF.

Transfusion. 2019 Jan;59(1):303-315. doi: 10.1111/trf.14966. Epub 2018 Oct 26.

PMID:
30362577
12.

Prospective Evaluation of a Practical Guideline for Managing Positive Sterility Test Results in Cell Therapy Products.

Panch SR, Bikkani T, Vargas V, Procter J, Atkins JW, Guptill V, Frank KM, Lau AF, Stroncek DF.

Biol Blood Marrow Transplant. 2019 Jan;25(1):172-178. doi: 10.1016/j.bbmt.2018.08.003. Epub 2018 Aug 9.

PMID:
30098394
13.

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

Green DS, Nunes AT, David-Ocampo V, Ekwede IB, Houston ND, Highfill SL, Khuu H, Stroncek DF, Steinberg SM, Zoon KC, Annunziata CM.

J Transl Med. 2018 Jul 16;16(1):196. doi: 10.1186/s12967-018-1569-5.

14.

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN.

J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.

15.

Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells.

Jin P, Chen W, Ren J, Chen S, Wood L, Zhao Y, Remaley A, Pham C, Lian S, Liu S, Liu H, Highfill S, Berzofsky JA, Stroncek DF.

Cytotherapy. 2018 May;20(5):728-739. doi: 10.1016/j.jcyt.2018.03.001. Epub 2018 Apr 11.

16.

Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System.

Vizcardo R, Klemen ND, Islam SMR, Gurusamy D, Tamaoki N, Yamada D, Koseki H, Kidder BL, Yu Z, Jia L, Henning AN, Good ML, Bosch-Marce M, Maeda T, Liu C, Abdullaev Z, Pack S, Palmer DC, Stroncek DF, Ito F, Flomerfelt FA, Kruhlak MJ, Restifo NP.

Cell Rep. 2018 Mar 20;22(12):3175-3190. doi: 10.1016/j.celrep.2018.02.087.

17.

Comparison of human bone marrow stromal cells cultured in human platelet growth factors and fetal bovine serum.

Ren J, Ward D, Chen S, Tran K, Jin P, Sabatino M, Robey PG, Stroncek DF.

J Transl Med. 2018 Mar 14;16(1):65. doi: 10.1186/s12967-018-1400-3.

18.

Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.

Jin J, Gkitsas N, Fellowes VS, Ren J, Feldman SA, Hinrichs CS, Stroncek DF, Highfill SL.

J Transl Med. 2018 Jan 24;16(1):13. doi: 10.1186/s12967-018-1384-z.

19.

Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Sukumar M, Vodnala SK, Hu J, Ji Y, Clever D, Black MA, Gurusamy D, Kruhlak MJ, Jin P, Stroncek DF, Gattinoni L, Feldman SA, Restifo NP.

JCI Insight. 2017 Dec 7;2(23). pii: 95103. doi: 10.1172/jci.insight.95103.

20.

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL.

Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.

21.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

22.

Cancer vaccine strategies: translation from mice to human clinical trials.

Berzofsky JA, Terabe M, Trepel JB, Pastan I, Stroncek DF, Morris JC, Wood LV.

Cancer Immunol Immunother. 2018 Dec;67(12):1863-1869. doi: 10.1007/s00262-017-2084-x. Epub 2017 Nov 15. Review.

23.

Comparative analyses of industrial-scale human platelet lysate preparations.

Pierce J, Benedetti E, Preslar A, Jacobson P, Jin P, Stroncek DF, Reems JA.

Transfusion. 2017 Dec;57(12):2858-2869. doi: 10.1111/trf.14324. Epub 2017 Oct 8.

24.

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less.

Stroncek DF, Shaw BE, Logan BR, Kiefer DM, Savani BN, Anderlini P, Bredeson CN, Hematti P, Ganguly S, Diaz MA, Abdel-Azim H, Ahmed I, Maharaj D, Seftel M, Beitinjaneh A, Seo S, Yared JA, Halter J, O'Donnell PV, Hale GA, DeFilipp Z, Lazarus H, Liesveld JL, Zhou Z, Munshi P, Olsson RF, Kasow KA, Szer J, Switzer GE, Chitphakdithai P, Shah N, Confer DL, Pulsipher MA.

Biol Blood Marrow Transplant. 2018 Jan;24(1):175-184. doi: 10.1016/j.bbmt.2017.09.013. Epub 2017 Sep 25.

25.

Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment.

Weinstein AM, Chen L, Brzana EA, Patil PR, Taylor JL, Fabian KL, Wallace CT, Jones SD, Watkins SC, Lu B, Stroncek DF, Denning TL, Fu YX, Cohen PA, Storkus WJ.

Oncoimmunology. 2017 Apr 28;6(6):e1322238. doi: 10.1080/2162402X.2017.1322238. eCollection 2017.

26.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

27.

Sources of Hematopoietic Stem and Progenitor Cells and Methods to Optimize Yields for Clinical Cell Therapy.

Panch SR, Szymanski J, Savani BN, Stroncek DF.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1241-1249. doi: 10.1016/j.bbmt.2017.05.003. Epub 2017 May 8. Review.

28.

Manufacturing Differences Affect Human Bone Marrow Stromal Cell Characteristics and Function: Comparison of Production Methods and Products from Multiple Centers.

Liu S, de Castro LF, Jin P, Civini S, Ren J, Reems JA, Cancelas J, Nayak R, Shaw G, O'Brien T, McKenna DH, Armant M, Silberstein L, Gee AP, Hei DJ, Hematti P, Kuznetsov SA, Robey PG, Stroncek DF.

Sci Rep. 2017 Apr 27;7:46731. doi: 10.1038/srep46731.

29.

Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy.

Anandi P, Tian X, Ito S, Muranski P, Chokshi PD, Watters N, Chawla U, Hensel N, Stroncek DF, Battiwalla M, Barrett AJ.

Cytotherapy. 2017 Jun;19(6):735-743. doi: 10.1016/j.jcyt.2017.03.010. Epub 2017 Apr 7.

PMID:
28395942
30.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

31.

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.

Stroncek DF, Lee DW, Ren J, Sabatino M, Highfill S, Khuu H, Shah NN, Kaplan RN, Fry TJ, Mackall CL.

J Transl Med. 2017 Mar 16;15(1):59. doi: 10.1186/s12967-017-1160-5.

32.

Autologous lymphapheresis for the production of chimeric antigen receptor T cells.

Allen ES, Stroncek DF, Ren J, Eder AF, West KA, Fry TJ, Lee DW, Mackall CL, Conry-Cantilena C.

Transfusion. 2017 May;57(5):1133-1141. doi: 10.1111/trf.14003. Epub 2017 Feb 24.

33.

Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients.

Castiello L, Sabatino M, Ren J, Terabe M, Khuu H, Wood LV, Berzofsky JA, Stroncek DF.

Clin Cancer Res. 2017 Jul 1;23(13):3352-3364. doi: 10.1158/1078-0432.CCR-16-2199. Epub 2017 Jan 10.

34.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

35.

Gene therapy simplified.

Ren J, Stroncek DF.

Blood. 2016 Nov 3;128(18):2194-2195. No abstract available.

36.

TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.

Wood LV, Fojo A, Roberson BD, Hughes MS, Dahut W, Gulley JL, Madan RA, Arlen PM, Sabatino M, Stroncek DF, Castiello L, Trepel JB, Lee MJ, Parnes HL, Steinberg SM, Terabe M, Wilkerson J, Pastan I, Berzofsky JA.

Oncoimmunology. 2016 Jul 1;5(8):e1197459. doi: 10.1080/2162402X.2016.1197459. eCollection 2016 Aug.

37.

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN.

Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.

38.

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, Dougherty S, Qin H, Klebanoff CA, Fry TJ, Gress RE, Kochenderfer JN, Stroncek DF, Ji Y, Gattinoni L.

Blood. 2016 Jul 28;128(4):519-28. doi: 10.1182/blood-2015-11-683847. Epub 2016 May 25.

39.

Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.

Stroncek DF, Ren J, Lee DW, Tran M, Frodigh SE, Sabatino M, Khuu H, Merchant MS, Mackall CL.

Cytotherapy. 2016 Jul;18(7):893-901. doi: 10.1016/j.jcyt.2016.04.003. Epub 2016 May 17.

40.

NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.

Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, McVicar DW, Weber A, Heikenwalder M, Greten TF.

Nature. 2016 Mar 10;531(7593):253-7. doi: 10.1038/nature16969. Epub 2016 Mar 2.

41.

Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.

Merchant MS, Bernstein D, Amoako M, Baird K, Fleisher TA, Morre M, Steinberg SM, Sabatino M, Stroncek DF, Venkatasan AM, Wood BJ, Wright M, Zhang H, Mackall CL.

Clin Cancer Res. 2016 Jul 1;22(13):3182-91. doi: 10.1158/1078-0432.CCR-15-2550. Epub 2016 Jan 28.

42.

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.

Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L.

Cytotherapy. 2016 Feb;18(2):151-9. doi: 10.1016/j.jcyt.2015.11.008. Epub 2015 Dec 23.

43.

Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies.

Cugno C, Deola S, Filippini P, Stroncek DF, Rutella S.

J Transl Med. 2015 Nov 16;13:362. doi: 10.1186/s12967-015-0724-5. Review.

44.

Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates.

Stroncek DF, Tran M, Frodigh SE, David-Ocampo V, Ren J, Larochelle A, Sheikh V, Sereti I, Miller JL, Longin K, Sabatino M.

Transfusion. 2016 Feb;56(2):511-7. doi: 10.1111/trf.13394. Epub 2015 Oct 27.

45.

Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency.

Salem B, Miner S, Hensel NF, Battiwalla M, Keyvanfar K, Stroncek DF, Gee AP, Hanley PJ, Bollard CM, Ito S, Barrett AJ.

Cytotherapy. 2015 Dec;17(12):1675-86. doi: 10.1016/j.jcyt.2015.08.008. Epub 2015 Sep 28.

46.

CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation.

Anand A, Anandi P, Jain NA, Lu K, Dunavin N, Hourigan CS, Le RQ, Chokshi PD, Ito S, Stroncek DF, Sabatino M, Barrett AJ, Battiwalla M.

Support Care Cancer. 2016 Feb;24(2):815-822. doi: 10.1007/s00520-015-2848-9. Epub 2015 Jul 21.

47.

Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers.

Shaw BE, Logan BR, Kiefer DM, Chitphakdithai P, Pedersen TL, Abdel-Azim H, Abidi MH, Akpek G, Diaz MA, Artz AS, Dandoy C, Gajewski JL, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Majhail NS, O'Donnell PV, Olsson RF, Savani BN, Schears RM, Stroncek DF, Switzer GE, Williams EP, Wingard JR, Wirk BM, Confer DL, Pulsipher MA.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1830-8. doi: 10.1016/j.bbmt.2015.06.013. Epub 2015 Jun 23.

48.

Protecting the Health and Safety of Cell and Tissue Donors.

Stroncek DF, England L.

ISBT Sci Ser. 2015 Apr 1;10(Suppl 1):108-114.

49.

Human bone marrow stromal cell confluence: effects on cell characteristics and methods of assessment.

Ren J, Wang H, Tran K, Civini S, Jin P, Castiello L, Feng J, Kuznetsov SA, Robey PG, Sabatino M, Stroncek DF.

Cytotherapy. 2015 Jul;17(7):897-911. doi: 10.1016/j.jcyt.2015.03.607. Epub 2015 Apr 14.

50.

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.

Shah NN, Baird K, Delbrook CP, Fleisher TA, Kohler ME, Rampertaap S, Lemberg K, Hurley CK, Kleiner DE, Merchant MS, Pittaluga S, Sabatino M, Stroncek DF, Wayne AS, Zhang H, Fry TJ, Mackall CL.

Blood. 2015 Jan 29;125(5):784-92. doi: 10.1182/blood-2014-07-592881. Epub 2014 Dec 1.

Supplemental Content

Loading ...
Support Center